• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Osteoarthritis News / Chondroitin Sulfate May Act as a Structure Modifying Agent in Knee Osteoarthritis

Chondroitin Sulfate May Act as a Structure Modifying Agent in Knee Osteoarthritis

February 26, 2009 By Arthritis Center

Severe Medial Compartment Knee OA
Severe Medial Compartment Knee OA

The efficacy of glucosamine and/or chondroitins in knee osteoarthritis (OA) has been controversial.  A recent large, randomized, multicenter trial (the GAIT trial) found no symptomatic or structure-modifying benefit of glucosamine or chondroitin, alone or in combination.  However, prior studies conducted in Europe using different formulations have suggested the possibility of structure modification with chondroitin sulfate (CS).  Here, Kahan et al (Arthritis Rheum 2009; 60(2): 524) explore the efficacy of CS in improving symptoms and delaying radiographic progression of symptomatic knee OA.

Methods

Subjects with painful medial tibiofemoral knee OA, without end-stage disease, were randomized 1:1 to receive CS (administered as an 800 mg dose of purified chondroitins 4 and 6 sulfate dissolved in water and taken daily) vs. identical placebo.  Subjects were enrolled in France, Belgium, Switzerland, and the U.S.  Subjects underwent follow-up fluoroscopically aligned knee radiographs at 12, 18, and 24 months with change in minimum joint space width (JSW) of the medial compartment predefined as the primary outcome measure.  OA symptoms and the used of allowed rescue medications (acetaminophen and NSAIDs) were assessed every 3 months.

Results

Among 1052 screened subjects, 622 were enrolled (n=313 placebo, n=309 CS).  A similar number of placebo and CS treated subjects completed the two years of the study (n=217 placebo subjects (69%) and n=206 CS subjects (67%)).  Women comprised 68% of enrolled subjects with a mean age of 62 years.  Most (57%) of subjects had advanced (Kellgren/Lawrence grade 3) knee OA with a mean duration of symptoms of approximately 6 years.  Baseline characteristics, including the minimum JSW width of the median compartment, were balanced between the two groups.

In intent-to-treat analyses, minimum medial JSW decreased in both the CS and placebo groups; however, the average decrease in minimum JSW at 24 months was significantly less in the CS treated group (-0.07 mm) compared to the placebo treated group (-0.31 mm) (p<0.001).  The percentage of those designated as having radiographic progression was 28% in the CS group vs. 41% in the placebo group (p<0.001), with the number needed to treat (NNT) to prevent radiographic progression of 8.  Treatment with CS was significantly more effective in subjects with higher baseline BMI.

Symptoms (measured with VAS for pain and WOMAC pain) decreased in both groups and were did not statistically differ at 24 months.  Adverse events were minimal and were balanced between the groups.

Conclusions

Daily use of CS was associated with a reduction in progression of joint space narrowing of the medial compartment of the knee in patients with painful knee OA.

Editorial Comment

The findings of this study differ from that of the GAIT trial, in which no structural benefit of chondroitins were detected.  The discrepancy in results could be related to differences in the agents used (the CS studied here is a regulated product produced as a prescription drug) or potentially in the way the outcomes were measured.  Whatever the reason, the differences between CS and placebo in delaying radiographic progression do appear to be robust.  Whether CS is a symptom modifier is less clear from this study, as early separation in symptoms was not maintained through the study interval, raising the question whether the mechanism under which CS protects cartilage may be disconnected from that which leads to pain.  Given the absence of disease modifying OA agents, these findings are promising, and deserve confirmation with longer term studies that include a hard outcome (i.e. need for joint replacement) and potentially a more sensitive measure of cartilage (i.e. with MRI) to be entirely convincing.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy